Registered Members Login:
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

121 Pages (Click to Jump) V  « < 113 114 115 116 117 118 119 > »    
Reply to this topic

post Posted: Oct 7 2006, 05:22 PM
  Quote Post

Posts: 8,075
Thanks: 429

In reply to: plastic on Friday 06/10/06 07:59am

Your post caught my attention plastic!! Anyone else got any comments about this stock!! Thanks in advance. biggrin.gif

post Posted: Oct 6 2006, 07:59 AM
  Quote Post

Posts: 9,177
Thanks: 283

I think it might pay to keep an eye on this company.

Come to think of it, it might pay to keep on eye on the people at the top of this company.

From this AM's SMH. I think the journo is probably speaking from ignorance more than anything else.

Rheumatics milestone

In the tiddlers department, biotech Phylogica yesterday announced "a major milestone in its rheumatoid arthritis program".
While the stock closed up 4c at 39c, investors will have to wait for a few more major milestones passed by the Perth company before it taps into the billions of dollars available for anti-rheumatic drugs.

Clinical trials are not likely to start for another three to five years. Investors must be satisfied with a peer-reviewed article in Nature Biotechnology as a basis for the big hopes.

What did Uncle Mel do to us?
post Posted: Aug 1 2006, 09:37 AM
  Quote Post

Posts: 2,469
Thanks: 289

Ferret's Stock to Watch: PHYLOGICA LIMITED
09:01, Tuesday, 1 August 2006


Sydney - Tuesday - August 1: (RWE Aust Business News)


Phylogica Ltd (ASX:PYC) reports international laboratory tests
have confirmed that its new Phylomer stroke drugs have suitable
properties to function as stroke therapies.
"What these data tell us is that these Phylomer drugs are very
stable in fresh human plasma and will last in the body for the optimal
amount of time needed to be an effective treatment for stroke," chief
executive Stewart Washer said.
The animal model tests are being undertaken in collaboration with
the University of Tasmania's commercial arm, UTAS Innovation and
Australian Neuromuscular Research Institute.
Dr Washer said the analysis of the drugs' properties in human
plasma and animals was an exciting milestone.
The half lives in animals of the Phylomers were 5 to 16 fold
better than the leading emergency stroke therapy, tissue plasminogen
activator which is administered by intravenous infusion.
"The human body can be quite a hostile environment," Dr Washer
"These findings show that Phylomers, which are protein-based
drugs, are actually resistant to damaging enzymes in the body that can
attack proteins.
"It's an important step to prove that Phylomers are able to keep
their effectiveness for long periods of time in humans."
Meanwhile, it has been a very busy and productive quarter for
Phylogica, closing a number of strategic deals and progressing new
partnering opportunities.
Phylogica was named as the biotech sector's top performer in the
first quarter of 2006 by independent analysts including
PriceWaterhouseCoopers and Bioshares.
Deals such as AstraZeneca's acquisition of Cambridge Antibody
Technology (CAT) this month - valued at $1.75 billion - highlights a
major shift in attitudes to the emerging field of antibody alternatives.
This is one of the hottest areas in drug discovery today.
"We are well positioned as a leader in the field of antibody
alternatives and major pharmaceutical companies are expressing interest
in our technology," Dr Washer said.
"Following our successful collaboration late last year in burns
treatment with 2005 Australian of the Year, Clinical Professor Fiona
Wood, we are building on our network of world-class partnerships".
In the first quarter, the company signed a commercial
collaboration with European biotechnology company, Opsona Therapeutics, a
leader in the immunology field.
It also signed deals with the Garvan Institute of Medical
Research in diabetes followed soon after by a deal with the Baker Heart
Research Institute in cardiac disease, who are closely associated with
the Alfred Hospital in Melbourne.
"Our partnering strategy is to target commercial and scientific
collaborations concurrently.
"The commercial collaborations will assist Phylogica to achieve
early revenue whilst the scientific collaborations will allow it to
accelerate the development of its internal drug discovery candidates,"
said Dr Washer.


Shares of Phylogica yesterday rose 3c to 54c. Rolling high for
the year has been 86 and low of 15c. The company has 74.1 million shares
on issue with a market cap of $37.8 million.
Non-executive chairman Joachim von Roy says Phylogica's
achievements in its first financial year has reached a new level of
"With the science well validated through key research
collaborations, we are now being recognised by international
pharmaceutical and biotechnology companies as a major player in the
Beyond Antibody space," Mr von Roy said.
"Already this year we have signed two major international
commercial deals.
"The most recent deal is with Johnson and Johnson Research, the
Australian research arm of the global pharmaceutical company Johnson and
Johnson to develop novel compounds using our Phylomer technology.
"The other is with European biotech, Opsona Therapeutics, which
has partnered with Wyeth Pharmaceuticals to develop anti-inflammatory
"Phylogica is currently in late stage negotiations with a number
of other biotechnology and large pharmaceutical companies, following the
management's team successful efforts at international conferences
attended this year, with more meetings planned in the next six months,"
the chairman declared.


Phylogica is a relative newcomer to the stock exchange list,
making its debut on March 30, 2005.
The company is a biopharmaceutical firm engaged in the discovery
and development of novel therapeutics directed at proteins and their
Phylogica is currently applying its proprietary technologies in
functional proteomics to the development of therapies for the treatment
of inflammatory diseases.
Common inflammatory pathways underpin diseases as diverse as
asthma, acute stroke damage and diabetes.
However, the potential applications of Phylogica's enabling
technologies are far more wide-ranging.
Phylogica's innovative proprietary technologies, which target
and block disease protein interactions, constitute a drug discovery
engine, designed to produce cost-effective therapies with fewer side
effects than existing treatments.
These drug therapies are made from small protein segments called
phylomers that are selected to be very specific at blocking only the
disease protein interaction.
Out of the company's library of phylomers a pipeline of drug
candidates has emerged for the treatment of stroke and asthma and the
company is in the early stages of the discovery of candidates to treat
obesity/Type II diabetes.
Phylogica's proprietary technologies are the result of close
collaboration between the Fox Chase Cancer Center in Philadelphia
and Australia's Telethon Institute for Child Health Research in Perth,
both of which are recognised for their excellence in medical research.
In addition, over a six-year period, Phylogica's technology has
received over $2.5 million in competitive peer-reviewed funding from
leading granting bodies including the National Institutes of Health in
the US and, in Australia, the National Health and Medical Research
Council (NHMRC), the Australian Research Council (ARC) and AusIndustry's
Biotechnology Innovation Fund program.
The company is led by an experienced management team and board
which are assisted by Phylogica's scientific advisory board, the
membership of which is drawn from some of the top research institutions
in the world.
Phylogica's proprietary technologies are protected by eight
patent families with four granted patents including in the US and
The company owns all of this intellectual property and continues
to extend its powerful intellectual property position in functional
proteomics with new patent filings.

post Posted: Jun 1 2006, 08:21 PM
  Quote Post

In reply to: goranche on Wednesday 10/05/06 01:28pm

This stock is going no where, an announcement has been imminent for the last six those selling down.

post Posted: May 10 2006, 01:28 PM
  Quote Post

Posts: 4

In reply to: crookers on Wednesday 10/05/06 01:06pm


I did a bit of research myself earlier on in the week.This Bio company seems to be concentrating on everyday health conditions which could only mean some good news or a breakthrough we can only hope.

post Posted: May 10 2006, 01:06 PM
  Quote Post

Posts: 244
Thanks: 1

Have heard the same rumour of a large deal and trading over the past few days supports it.


post Posted: May 10 2006, 01:01 PM
  Quote Post

Posts: 4

In reply to: bigjack on Wednesday 10/05/06 12:04pm

Could we get 10% today cause there is just not enough sellers. I smell an announcement it could be big I mean real big.

post Posted: May 10 2006, 12:04 PM
  Quote Post

Posts: 31

In reply to: goranche on Tuesday 09/05/06 04:47pm

Starting to heat up........ lmaosmiley.gif

post Posted: May 9 2006, 04:47 PM
  Quote Post

Posts: 4

In reply to: awol on Saturday 25/03/06 06:08am

[QUOTE]Watch it go north before Friday. smile.gif

Around .70 next stop $1. After announcement I think!

post Posted: May 2 2006, 02:23 PM
  Quote Post

Posts: 3,268
Thanks: 9

user posted image

Recent Radio Broadcast (Tue, 02 May 2006 11:30AM):
PYC - Market Briefing - Dr Stewart Washer, CEO

N.B. Radio can normally be accessed by the 'RADIO' link, top of every page.

------------------------------------------------------------------------------------------------------------- Radio delivers investor presentations from ASX listed companies. Keep up to date with the latest corporate dealings of the shares you follow. Hear news direct from the source. Listen to directors and investor relations mangers discuss their company, give investor updates and brief on current results. Radio keeps you informed about company announcements and events, and provides you daily market wraps and industry discussions.


121 Pages (Click to Jump) V  « < 113 114 115 116 117 118 119 > » 

Back To Top Of Page
Reply to this topic

You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.